GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » Revenue per Share

GB Sciences (GB Sciences) Revenue per Share : $0.00 (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is GB Sciences Revenue per Share?

GB Sciences's revenue per share for the three months ended in Dec. 2023 was $0.00. GB Sciences's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for GB Sciences's Revenue per Share or its related term are showing as below:

During the past 13 years, GB Sciences's highest 3-Year average Revenue Per Share Growth Rate was 195.00% per year. The lowest was -4.30% per year. And the median was 95.35% per year.

GBLX's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

GB Sciences Revenue per Share Historical Data

The historical data trend for GB Sciences's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Revenue per Share Chart

GB Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 - - -

GB Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GB Sciences's Revenue per Share

For the Biotechnology subindustry, GB Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GB Sciences's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where GB Sciences's PS Ratio falls into.



GB Sciences Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

GB Sciences's Revenue Per Share for the fiscal year that ended in Mar. 2023 is calculated as

Revenue Per Share (A: Mar. 2023 )=Revenue (A: Mar. 2023 )/Shares Outstanding (Diluted Average) (A: Mar. 2023 )
=0/357.721
=0.00

GB Sciences's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=0/403.172
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GB Sciences  (OTCPK:GBLX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


GB Sciences Revenue per Share Related Terms

Thank you for viewing the detailed overview of GB Sciences's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GB Sciences (GB Sciences) Business Description

Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.
Executives
John C Poss director, officer: Chief Executive Officer
Craig Ellins director, 10 percent owner, officer: CEO 3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp 10 percent owner C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp 10 percent owner C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206

GB Sciences (GB Sciences) Headlines

From GuruFocus

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

By GuruFocusNews GuruFocusNews 01-11-2022

UPDATE: Gb Sciences Issues Shareholder Letter

By GuruFocusNews GuruFocusNews 03-16-2022